Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00379184 |
| Other study ID # |
ON-04-014-MBL |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
September 19, 2006 |
| Last updated |
March 28, 2014 |
| Start date |
September 2006 |
| Est. completion date |
June 2009 |
Study information
| Verified date |
March 2014 |
| Source |
Northern Orthopaedic Division, Denmark |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Denmark: The Danish National Committee on Biomedical Research EthicsDenmark: Danish Dataprotection Agency |
| Study type |
Observational
|
Clinical Trial Summary
Musculoskeletal pains represent a major part of pain complaints in patients. Moreover, the
treatment of musculoskeletal pain conditions by currently available drugs is not optimal
(Curatolo and Bogduk 2001). Thus, deep pain is a diagnostic and therapeutic problem, and
further insights into the peripheral and central neurophysiologic mechanisms are necessary
to improve diagnosis and therapy and to implement a mechanism-based approach. Peripheral
sensitization and central hyper excitability are, most likely the important factors for
chronic musculoskeletal pain and in particular osteoarthritis (OA).
The focus of this project is to study the involvement of peripheral and central
sensitization underlying deep tissue hyperalgesia and referred pain in male and female OA
patients.
Adequate quantitative sensory testing assessment techniques for measuring hyper excitability
are needed to investigate, in more detail the mechanisms involved in generating the
sensitization in OA patients.
Description:
Methods
General procedure:
In the Outpatient Department of Clinic Farsoe, Northern Orthopaedic Division patients
eligible for participating in the study will be informed and asked to participate. Those who
agree and sign the informed consent will be scheduled for the investigational procedures to
be performed at the SMI as soon as possible.
At the SMI all patients are interviewed and assessed with the following three procedures
with at least 10 minutes between procedures. Duration of visit will be approximately 3 hours
in one session.
Procedure 1:
Pressure pain sensitivity and temporal summation of pressure pain
Equipment: computer controlled pressure algometer.
Sites: knee, tibialis anterior, forearm
- Stimulus intensity: pressure pain threshold
- Stimuli number: 10
- Frequency: ISI 1s
- Pain rating: pain intensity, pressure pain threshold, unpleasantness and
after-sensations will be collected.
General:
Pressure pain sensitivity and temporal summation of pressure are tested on bilateral knee,
tibialis anterior muscle and forearm. Test sites are located and marked according to the
landmark stated below. Pressure pain threshold of these test sites are measured first.
Sequential stimulations are applied to these test sites respectively to test the pain
perception for each press stimulus. Unpleasantness and after-sensations are collected after
cessation of sequential stimulation to evaluate the affective aspect of pain.
Specific:
Seven test sites (2 cm proximal to the superior lateral edge of patella, 2 cm proximal to
the superior edge of patella, 2 cm proximal to the superior medial edge of patella, 2 cm
distal to the inferior lateral edge of patella, 2 cm distal to the inferior medial edge of
patella, 5 cm lateral to the superior lateral edge of patella and 5 cm medial to the
superior medial edge of patella) are marked around the knee. The site for measuring temporal
summation of pain is the most sensitive site among these five sites.
The test site on the arm is 7 cm distal to the lateral humeral epicondyle on the line
connecting the lateral epicondyle and the styloid process of the radius, located on the
extensor carpi radialis longus muscle.
The test site on the leg is at the tibialis anterior (TA) muscle 14 cm distal to the
inferior lateral edge of the patella.
Pressure pain threshold on these test sites are measured. A mechanical pressure stimulus
with gradient of 0.3 kg/s will be applied until the subject reports pain and presses a stop
button. The PPT measurements start from the contralateral knee of the affected knee.
Sequential stimulation consists of 10 pressure stimuli (1 sec duration) at the pressure pain
threshold level. Inter-stimulus interval (ISI) is set to 1 sec. Skin contact between the
individual pressure stimuli will be ensured by keeping a constant force of 0.1 kg; i.e.
during the series of sequential stimulation the probe has skin contact and is first
withdrawn after 10 stimulations. The subjects rate the pain intensity continuously during
the sequential stimulation on an electronic visual analogue scale (VAS) on which "0"
indicates "no pain" and "10 cm" indicates "maximal pain". Sequential stimulation is to be
applied on each test site with at least a 1 min interval. The sequence of test sites is
chosen in a randomized way to minimize order effects.
Unpleasantness and after-sensations are collected 15 sec after cessation of sequential
stimulation.
Procedure 2:
Referred pain
Equipment: computer controlled pressure algometer, computer-controlled auto-infusion syringe
pump.
- Site: tibialis anterior
- Concentration: 6% hypertonic saline.
- Method: continuous infusion.
- Pain rating: pain intensity, pain area drawing (primary and secondary pain area),
pressure pain threshold, unpleasantness and after-sensations will be collected.
General:
Hypertonic saline is infused into the tibialis anterior (TA) muscle to elicit local and
referred pain. The experiment will be conducted in one leg at a time, by giving a single
bolus infusion of hypertonic saline with a time interval of approximately 20 min between
each leg. Test sites are located and marked on the TA. Pressure pain thresholds on injection
site and front side of ankle are measured before infusion. Hypertonic saline is infused by
using a computer-controlled syringe pump. Subjects report pain intensity and draw the pain
area induced by infusion. Pressure pain thresholds on injection site and front side of ankle
are measured 10 min after infusion- evoked-pain disappears. Unpleasantness and
after-sensations for the evoked pain are collected as well.
Specific:
Injection site is placed at the belly of the TA 14 cm distal to the inferior lateral edge of
the patella on both legs. At the marked site in the TA a 24G - 40 mm needle will be inserted
vertically until a piercing of the muscle fascia is felt, at a depth of approximately 20 mm
from the skin surface. Then the plunger of the syringe will be withdrawn to ensure that the
needle is deep in the muscle and not in a blood vessel. The needle will then be connected
through a polyethylene extension tube (Vygon, France, No. 1155.70) to a 10 ml syringe fitted
in a computer-controlled auto-infusion syringe pump (Terumo Terufusion syringe pump, model
STC-S27, Type CG). A total volume of 0.5 ml sterile 6% hypertonic saline (58.5 mg/ml,
Sygehus Apotekerne, Denmark) will be infused over 20 s into the TA muscle (infusion-rate 90
ml/h).
The pain intensity response is scored on a visual analogue scale (VAS) after the infusion.
The subjects mark the painful region(s) on pain maps after the infusion. Local pain is
defined as the pain area drawn at the infusion site, referred pain is defined as the pain
areas drawn away from the infusion site and radiating pain is defined as the pain areas
drawn radiating from the local site into the other regions of the leg.
Pressure pain thresholds on injection site and front side of ankle are measured before and
10 min after infusion when infusion evoked pain disappears.
Unpleasantness and after-sensations for the evoked pain are collected afterwards.
Procedure 3:
Cuff pressure pain and DNIC
Equipment: computer controlled cuff algometer.
- Site: upper arms
- Pain rating: pain intensity, cuff pressure pain threshold, pressure pain threshold,
unpleasantness and after-sensations collected.
General:
Continuous cuff pressure stimulation is applied to measure the inhibitory control of the
pain sensory system. Cuff stimulation is applied to bilateral upper arms and tibialis
anterior (location see procedure 1). Pressure pain threshold on the test sites around knee,
on the ipsilateral and contralateral arm (on the belly of biceps brachii) are measured
before, during and after cuff pressure stimulation. Cuff pressure stimulation is applied by
computer-controlled cuff algometer to induce continuous pain perception for 10 min. Pain
intensity of ongoing pain in the stimulated limb and affected knee are rated on electrical
VAS.
Specific:
The cuff is wrapped around the middle of both arms. The lower rim of the tourniquet cuff
(7.5 cm wide) is at least 3 cm proximal to the cubital fossa. The setup of the cuff
algometer is programmed to stop the pressure increase at a preset pain intensity of 4 cm on
the VAS and to automatically adjust the pressure to maintain the obtained pain within ±0.5
cm VAS for 10 min or until the subject presses the stop button. If the pain increases over
the upper pain limit, the system decreases the pressure until the pain returns into the
'target' zone and vice versa.
When the VAS rise up to 4 cm and keep constant for 1 min, we will measure PPTs on the same
test sites except tested arm. Pain intensity of ongoing pain in affected knee and arm which
is not stimulated is rated on another electrical VAS during cuff pressure stimulation. Five
minutes following deflation, pain intensity of ongoing pain in affected knee and arms is
rated. Fifteen minutes following deflation, PPTs are measured on the test sites.
The sequence of test limb is chosen at random to minimize order effects.
